Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 3/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7052284 | 0.80 | NOS2 (0.60) | NOS2 | |
| SCHEMBL6106716 | 0.79 | CYP4F2 (0.45) | NOS2TBXAS1 | |
| SCHEMBL2880078 | 0.79 | HSP90AB1 (0.45) | MAPTALDH1A1 | |
| SCHEMBL6790619 | 0.79 | TBXAS1 (0.43) | F13A1MAPTALDH1A1RXFP1TBXAS1 | |
| Adipic Acid SCHEMBL28157079 | 0.75 | LMNA (0.58) | PPARAALDH1A1 | |
| Adipic Acid SCHEMBL28157078 | 0.75 | LMNA (0.58) | PPARAALDH1A1 | |
| SCHEMBL7468038 | 0.75 | NOS2 (0.58) | NOS2 | |
| Hydrochloric Acid SCHEMBL7049243 | 0.74 | NOS2 (0.61) | NOS2 | |
| SCHEMBL26547322 | 0.73 | MAPT (0.47) | MAPTRXFP1TBXAS1 | |
| SCHEMBL3740210 | 0.73 | ALDH1A1 (0.43) | MAPTALDH1A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153862-B2 | αv integrin receptor antagonists | MERCK & CO., INC. (US) | 2006-12-26 | — | — | US | disclosed |
| US-6693101-B2 | ALKANOIC ACID DERIVATIVE; INTEGRIN RECEPTOR ANTAGONIST | MERCK & CO., INC. | 2004-02-17 | — | — | US | disclosed |
| US-20040019037-A1 | Alpha V integrin receptor antagonists | ASKEW BEN C (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1254116-A4 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2003-04-23 | — | — | EP | disclosed |
| EP-1254116-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-11-06 | — | — | EP | disclosed |
| US-20010053853-A1 | Alpha V integrin receptor antagonists | MERCK & CO., INC. | 2001-12-20 | — | — | US | disclosed |
| WO-2001053262-A1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019037-A1 | Alpha V integrin receptor antagonists | ITGAV, ADGRE5, ITGA5 | F13A1 164/4885PPARA 870/4885MAPT 4460/4885 |
| US-20010053853-A1 | Alpha V integrin receptor antagonists | ITGAV, ADGRE5, ITGA5 | F13A1 164/4885PPARA 870/4885MAPT 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.